Updated:
ImmuCell
ImmuCell is a NASDAQ-listed animal health company in Portland, ME, developing USDA-licensed products for dairy and beef cattle led by CEO Michael Brigham.
ImmuCell
ImmuCell was founded in 1982 and is headquartered in Portland, Maine. Michael Brigham, who has been CEO since 1989, leads the publicly traded company focused on animal health. The firm is not a family office or asset manager; it operates as a commercial-stage biotechnology company manufacturing products for the dairy and beef industries. Its primary wealth creation comes from commercializing its own FDA and USDA-licensed biological products. The company's signature product is First Defense, a USDA-licensed immediate-use colostrum replacer for the prevention of scours in newborn calves. Its pipeline centers on Re-Tain, a treatment for subclinical mastitis in lactating dairy cows that has been under development for over a decade. ImmuCell completed construction of a dedicated manufacturing facility in Portland to produce Re-Tain at scale, investing heavily in its own capacity. The business model relies on selling directly to dairy and beef producers, with a geographic footprint concentrated in the United States and Canada. With roughly 80 employees, the firm operates from its single headquarters location in Maine. Operational focus in the last two years has been on achieving regulatory milestones for Re-Tain. March 2024: The FDA confirmed the withdrawal of a related submission, clearing the way for ImmuCell to complete the remaining technical sections for product approval (per the firm, March 2024). This resubmission effort marks the most significant corporate event in recent years, as Re-Tain's approval would meaningfully expand the firm's addressable market into mastitis treatment. ImmuCell's structural posture is distinct because it positions itself as a fully integrated manufacturer, not a licensing-and-royalty biotech. By owning the entire production process for its biologicals in-house, including the Re-Tain facility, the company maintains control over quality and supply but also carries the full operational burden of a manufacturing enterprise on its small-cap balance sheet.
General information
Firm type
other
Year founded
1982
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Portland
Corporate office
Portland, ME, United States
Principals
Michael F. Brigham
President and Chief Executive Officer
Sector focus
Frequently asked questions
What regulatory milestones is ImmuCell currently focused on?
ImmuCell's primary regulatory focus is completing the FDA submission for Re-Tain, a treatment for subclinical mastitis in lactating dairy cows. In March 2024, the company announced that the FDA had accepted the withdrawal of a previously filed CMC technical section, allowing the firm to re-submit that component. Full product approval is the single most consequential regulatory event for the company's growth trajectory.
How does ImmuCell manufacture its products?
ImmuCell follows an integrated manufacturing model, owning and operating its own production facilities rather than outsourcing to contract manufacturers. The firm completed a dedicated facility in Portland, Maine specifically for the production of Re-Tain. Its flagship product, First Defense, is also manufactured in-house, providing the company with direct supply-chain control.
What is the competitive moat around First Defense?
First Defense holds USDA licensing for an immediate-use scours preventative for newborn calves, a product category with no direct generic competitors in the United States. The product's biological nature — a colostrum replacer derived from hyperimmunized cows — creates a natural barrier to exact replication. This regulatory and biological exclusivity supports ImmuCell's longstanding commercial position.
Does ImmuCell face any direct generic competition?
To date, First Defense has not faced directly interchangeable generic competition, protected by its specific USDA biological license. The Re-Tain program, if approved, would enter the mastitis treatment market where traditional intramammary antibiotics are the standard of care. Re-Tain's differentiation is its non-antibiotic biological mechanism and zero milk-discard label claim, targeting a specific segment of the market.
Who runs investment decisions at ImmuCell?
As a publicly traded operating company rather than an investment firm, capital allocation decisions rest with CEO Michael Brigham and the board of directors. Major investments, such as the construction of the Re-Tain manufacturing facility, are corporate strategy decisions approved through standard public-company governance. The company does not operate a portfolio of external investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: